

Pembrolizumab KEYNOTE-181

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



#### Other adjustments



Pembrolizumab KEYNOTE-181

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Locally advanced or metastatic oesophageal or OGJ carcinoma that is not amenable to surgical resection or definitive CRT after  $\geq 1$  prior lines of systemic therapy for patients with tumours of squamous cell histology that express PD-L1 (CPS  $\geq 10$ )

Experimental Arm: Pembrolizumab

Control Arm: Chemotherapy



